Browsing Tag
AD109
1 post
Sleep apnoea biotech Apnimed (APMD) climbs in Nasdaq debut after upsized offering
Apnimed raised $192M in an upsized Nasdaq IPO to fund oxnimbi's launch, with the FDA's February 28, 2027 decision on the first oral OSA pill now the pivot.